HC Wainwright Reiterates Buy Rating for Travere Therapeutics (NASDAQ:TVTX)

HC Wainwright reiterated their buy rating on shares of Travere Therapeutics (NASDAQ:TVTX) in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $19.00 target price on the stock. HC Wainwright also issued estimates for Travere Therapeutics’ FY2026 earnings at $0.13 EPS.

Several other brokerages have also issued reports on TVTX. Wells Fargo & Company lifted their target price on shares of Travere Therapeutics from $8.00 to $9.00 and gave the company an equal weight rating in a research report on Friday, February 16th. Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $15.00 to $18.00 and gave the stock a buy rating in a research report on Tuesday. Wedbush reissued an outperform rating and issued a $13.00 price target on shares of Travere Therapeutics in a research note on Wednesday, April 17th. Guggenheim restated a neutral rating on shares of Travere Therapeutics in a research note on Wednesday, March 27th. Finally, Piper Sandler boosted their price objective on shares of Travere Therapeutics from $10.00 to $11.00 and gave the stock a neutral rating in a research report on Thursday, January 18th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $16.69.

Travere Therapeutics Stock Up 0.9 %

Shares of Travere Therapeutics stock opened at $6.66 on Tuesday. The firm’s 50 day moving average price is $6.97 and its 200-day moving average price is $7.59. The company has a market cap of $506.89 million, a P/E ratio of -4.10 and a beta of 0.69. The company has a quick ratio of 3.41, a current ratio of 3.47 and a debt-to-equity ratio of 1.88. Travere Therapeutics has a 52-week low of $5.12 and a 52-week high of $19.54.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Monday, May 6th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%. The firm had revenue of $41.40 million during the quarter, compared to analysts’ expectations of $43.46 million. During the same quarter last year, the business earned ($1.27) EPS. The business’s revenue was up 34.0% on a year-over-year basis. On average, sell-side analysts predict that Travere Therapeutics will post -3.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds have recently added to or reduced their stakes in TVTX. Armistice Capital LLC increased its position in shares of Travere Therapeutics by 0.7% during the third quarter. Armistice Capital LLC now owns 7,500,000 shares of the company’s stock worth $67,050,000 after acquiring an additional 50,000 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Travere Therapeutics by 10.9% in the third quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company’s stock worth $41,727,000 after purchasing an additional 460,176 shares in the last quarter. Kynam Capital Management LP grew its position in Travere Therapeutics by 105.6% in the fourth quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company’s stock valued at $17,980,000 after purchasing an additional 1,027,398 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Travere Therapeutics by 9.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,671,770 shares of the company’s stock valued at $14,946,000 after buying an additional 146,970 shares during the last quarter. Finally, Finepoint Capital LP lifted its position in Travere Therapeutics by 60.2% during the 4th quarter. Finepoint Capital LP now owns 1,435,321 shares of the company’s stock worth $12,904,000 after buying an additional 539,500 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.